Search - tctmd.com

Displaying 541 - 560 of 807

Sort: Relevancy | Date

Presentation TCT 2014

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Presenter: John M. Lasala, Stuart J. Pocock, George Hanzel, MD

September 16, 2014

Presentation TCT 2014

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

Presenter: Rajiv Tayal

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

Presenter: George Hanzel

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

Featured Presentation: Vorapaxar Safety and Efficacy Results in the FDA-Approved, Stroke-Free MI and PAD Populations

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Marc Bonaca

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Stefan C. Bertog

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Against the Proposal!

Presenter: Tudor G. Jovin

September 14, 2014

Presentation TCT 2014

For the Proposal!

Presenter: Philip M. Meyers

September 14, 2014

Presentation TCT 2014

Can LAA Closure Become the New Standard for Stroke Prevention?

Presenter: Hilary Nierenberg, Julie Logan, Saibal Kar

September 14, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2014

TCT 685: Costs of Periprocedural Complications Among Patients Treated with a Self-Expanding Transcatheter Aortic Valve Prosthesis: Results from the CoreValve US Pivotal Extreme-Risk Study

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Suzanne Baron

September 14, 2014

Presentation TCT 2014

TCT 664: Cardiac Magnetic Resonance Versus Transthoracic Echocardiography for the Assessment and Quantification of Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Henrique B. Ribeiro

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ian T. Meredith

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Susheel Kodali

September 14, 2014

Presentation TCT 2014

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ronald M. Lazar

September 14, 2014

Presentation TCT 2014

Strokes After TAVR II: Management Considerations (Current and Future)

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Nicolas M. van Mieghem

September 14, 2014

Presentation TCT 2014

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb

September 14, 2014

Advertisement

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Featured Presentation: Vorapaxar Safety and Efficacy Results in the FDA-Approved, Stroke-Free MI and PAD Populations

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Against the Proposal!

For the Proposal!

Can LAA Closure Become the New Standard for Stroke Prevention?

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

TCT 685: Costs of Periprocedural Complications Among Patients Treated with a Self-Expanding Transcatheter Aortic Valve Prosthesis: Results from the CoreValve US Pivotal Extreme-Risk Study

TCT 664: Cardiac Magnetic Resonance Versus Transthoracic Echocardiography for the Assessment and Quantification of Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Strokes After TAVR II: Management Considerations (Current and Future)

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content